A 6-week study to evaluate the combination of valsartan/HCTZ [hydrochlorothiazide] (160/12.5mg with forced titration to a maximum dose of 320/25mg) compared to valsartan monotherapy (160mg with forced titration to 320mg) as initial therapy in patients with severe hypertension.

Trial Profile

A 6-week study to evaluate the combination of valsartan/HCTZ [hydrochlorothiazide] (160/12.5mg with forced titration to a maximum dose of 320/25mg) compared to valsartan monotherapy (160mg with forced titration to 320mg) as initial therapy in patients with severe hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Valsartan/hydrochlorothiazide (Primary) ; Valsartan
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual initiation date (Nov 2005) added as reported by ClinicalTrials.gov.
    • 05 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top